Do you recommend the use of molecular assays to determine the need for neoadjuvant chemotherapy in select patients with HR+/HER2- breast cancer?
In patients with resectable HR+/HER2- breast cancer when would you start with preoperative chemotherapy and do you recommend the use of molecular assays to select patients for this approach?